{"filings":[{"id":2061036,"accession_number":"0001802768-26-000014","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2026-08-05T11:33:09+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q2 Royalty Receipts up 14% to $768M; raises FY 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 Royalty Receipts $768M (+14% YoY); Portfolio Receipts $773M (+6%).","Raised FY 2026 Portfolio Receipts guidance to $3.4B-$3.5B (from $3.325B-$3.45B).","Acquired royalty on AstraZeneca's cliramitug for up to $425M ($125M upfront) in July.","Capital Deployment YTD $1.1B; announced transactions value $1.7B.","Paid Q2 dividend $0.235/share; repurchased $45M in shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861317,"accession_number":"0001193125-26-257432","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2026-06-04T20:15:59+00:00","items":["5.07"],"status":"ready","headline":"Royalty Pharma announces 2026 AGM results; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 9 director nominees elected with 88.08% quorum; Pablo Legorreta received 458.2M votes for, 29.4M against.","Say-on-pay (non-binding) approved: 476.0M for, 11.1M against, 0.7M abstain.","Ratification of Ernst & Young as independent auditor: 506.3M for, 0.8M against, 1.0M abstain.","UK statutory accounts and reports approved: 487.2M for, 98K against, 0.6M abstain.","Authorization to allot shares without pre-emption passed: 445.7M for, 42.0M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":721641,"accession_number":"0001193125-26-245163","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2026-05-28T20:01:40+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Royalty Pharma enters new $1.8B unsecured revolver maturing 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.8B unsecured revolving credit facility replaces existing agreement from 2021.","Matures May 22, 2031; interest rate based on SOFR or base rate plus margin per pricing grid.","Covenants: leverage ratio ≤4.00x (4.50x post-acquisition), portfolio cash flow ≤5.00x (5.50x), coverage ≥2.50x.","Borrower: Royalty Pharma Holdings Ltd; guarantors: Royalty Pharma plc and Royalty Pharma Manager, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95571,"accession_number":"0001802768-26-000008","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q1 Portfolio Receipts +10% to $925M; raises FY 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Royalty Receipts grew 13% to $887M; driven by Tremfya (+79%), Voranigo (+140%), Evrysdi (+51%).","Adjusted EBITDA non-GAAP $889M (+21% YoY); Portfolio Cash Flow $722M (+18%).","Full-year 2026 Portfolio Receipts guidance raised to $3,325M-$3,450M (prev. $3,275M-$3,425M).","Announced up to $1.25B in royalty transactions; $528M capital deployed in Q1.","Recorded $69M non-cash impairment on Tazverik; positive Phase 3 data for daraxonrasib and Myqorzo."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":630576000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95570,"accession_number":"0001193125-26-152145","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Royalty Pharma triggers $250M milestone after positive daraxonrasib Phase 3 results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revolution Medicines' RASolute 302 trial met primary and key secondary endpoints (PFS and OS) in metastatic PDAC.","Royalty Pharma funded $250M upfront; positive data triggers additional $250M milestone, total $500M funded.","Royalty Pharma now earns 4.55% tiered royalty on daraxonrasib sales up to $2B, lower rates above $2B.","Additional $750M synthetic royalty available upon FDA approval and other milestones; first $250M on approval.","Senior secured loan of up to $750M available; first $250M tranche must be drawn after FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108729,"accession_number":"0001802768-26-000002","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Reports Q4 and Full Year 2025 Results; Portfolio Receipts Up 18% and 16% Respectively","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Portfolio Receipts reached $874M in Q4 2025 (up 18%) and $3,254M for FY 2025 (up 16%).","Net cash from operating activities was $827M in Q4 and $2,490M for FY 2025.","Deployed $2.6B in capital on royalty transactions in 2025, including nine new therapies.","Repurchased 37M shares for $1.2B and increased quarterly dividend by 7% to $0.235.","Provided FY 2026 guidance: Portfolio Receipts expected between $3,275M and $3,425M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2378193000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125187,"accession_number":"0001193125-25-328759","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Royalty Pharma CLO George Lloyd to step down; Arthur McGivern to assume role Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George W. Lloyd transitions from EVP and Chief Legal Officer effective Dec 31, 2025.","Lloyd will remain employed as a senior advisor to the Company.","Arthur R. McGivern, EVP and General Counsel, assumes CLO responsibilities on Jan 1, 2026.","McGivern joined Royalty Pharma in Oct 2022 from Goodwin Procter LLP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125186,"accession_number":"0001193125-25-328100","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"FDA approves Cytokinetics' MYQORZO; Royalty Pharma to receive 4.5% royalty on sales up to $5B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Pharma entitled to 4.5% royalty on MYQORZO sales up to $5B, decreasing to 1% above $5B.","Long-term capital of $225M fully drawn; launch capital of $225M with $50M drawn to date.","Royalty Pharma to receive $523M in quarterly repayments over 10 years (1.9x); $20M repaid through Sep 2025.","Following approval, Cytokinetics can draw additional $175M within 12 months, repayable at 1.9x over 10 years.","MYQORZO (aficamten) approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125185,"accession_number":"0001802768-25-000113","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q3 Portfolio Receipts +11% to $814M; raises FY guidance to $3,200-$3,250M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Portfolio Receipts $814M (+11% YoY); Royalty Receipts $811M (+11%). Net cash ops $703M.","Raised FY 2025 guidance: Portfolio Receipts now $3,200-$3,250M (14-16% growth, previously $3,050-$3,150M).","Adjusted EBITDA $779M, Portfolio Cash Flow $657M. Capital Deployment $1.0B in Q3 (Imdelltra, obexelimab, Amvuttra).","Repurchased 4M shares for $152M in Q3; $1.2B YTD share repurchases.","Issued $2B senior notes at 5.16% in Sep; repaid $1B notes in Aug; total debt $9.2B at 3.75% avg cost."],"consensus_eps_estimate":null,"consensus_eps_actual":1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1756203000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141905,"accession_number":"0001193125-25-204983","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Royalty Pharma prices $2B senior notes in three tranches: 2031, 2035, 2055","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$600M 4.450% notes due 2031, $900M 5.200% notes due 2035, $500M 5.950% notes due 2055.","Notes are senior unsecured and guaranteed by Royalty Pharma Holdings Ltd and RP Manager LLC.","Issuance closed September 16, 2025; interest payments begin March 25, 2026.","Underwriters include BofA, Goldman Sachs, J.P. Morgan, Morgan Stanley, and TD Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141904,"accession_number":"0001193125-25-179892","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Henry Fernandez steps down as Lead Independent Director of Royalty Pharma board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fernandez resigned effective August 13, 2025, after five years on the board.","No disagreement with the company; departure is voluntary.","Board thanks Fernandez for his service and contributions.","Company intends to name a new Lead Independent Director in the near future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141903,"accession_number":"0001193125-25-173988","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q2 Portfolio Receipts +20% to $727M; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Portfolio Receipts $727M (+20% YoY); Royalty Receipts $672M (+11%), driven by Voranigo, Trelegy, Evrysdi, Tremfya.","Raised FY 2025 Portfolio Receipts guidance to $3.05B-$3.15B (was $2.975B-$3.125B).","Capital deployment of $595M in Q2; $1B in share repurchases in H1 2025 (31M shares).","Completed acquisition of external manager RP Management in May, making Royalty Pharma an integrated company.","Entered up to $2B funding arrangement with Revolution Medicines, including $1.25B synthetic royalty on daraxonrasib."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1146912000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141902,"accession_number":"0001193125-25-160293","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Royalty Pharma appoints Carole Ho and Elizabeth Weatherman to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carole Ho (CMO of Denali Therapeutics) and Elizabeth Weatherman (Special LP at Warburg Pincus) appointed effective July 17, 2025.","Independent board representation increases to >90% following external manager acquisition.","Both directors determined independent under Nasdaq standards; no family relationships with officers or directors.","They will receive compensation per Independent Director Compensation Policy detailed in April 2025 Proxy Statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159834,"accession_number":"0000950103-25-006186","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["2.01","1.01","2.03","5.02","5.03","9.01"],"status":"ready","headline":"Royalty Pharma closes acquisition of RP LLC; $200M cash, shares, and $380M debt assumed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Paid $200M cash plus 24,530,266 non-voting Class E shares; assumed RP Management's $380M term loan.","Share consideration to Pablo Legorreta vests over 5 years; other management members vest over 10 years.","Joinder of Royalty Pharma Holdings Ltd and RP LLC as borrowers under existing $380M term loan; RP Management released.","Amended exchange agreement allows recipients to exchange RPH non-voting shares for Royalty Pharma Class A shares.","Amended articles of association of Royalty Pharma plc and RPH to reflect new share classes and procedural refinements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159833,"accession_number":"0001193125-25-117771","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Royalty Pharma shareholders approve internalization deal; all director nominees elected","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Proposal 2 (Membership Interest Purchase Agreement internalization) approved with 440.5M For, 74K Against.","All nine director nominees elected, including Pablo Legorreta, Henry Fernandez, Bonnie Bassler.","Advisory say-on-pay (Proposal 7) passed with 403.2M For, 36.8M Against.","Appointment of Ernst & Young as auditor ratified with 493.5M For, 116K Against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159832,"accession_number":"0001193125-25-115482","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q1 Portfolio Receipts $839M (+17% YoY); raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Royalty Receipts grew 12% to $788M; cystic fibrosis franchise, Trelegy, Xtandi drove growth.","Raised FY2025 Portfolio Receipts guidance to $2,975M-$3,125M (prior $2,900M-$3,050M).","Repurchased 23M shares for $723M under new $3B buyback program.","Internalization of manager RP Management ($1.1B) vote May 12, closing expected Q2 2025.","Biogen R&D funding for litifilimab (up to $250M); $50M upfront in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":568247000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159831,"accession_number":"0001140361-25-013380","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Royalty Pharma amends purchase agreement to issue Class B shares to sellers at closing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment No. 1 adds Royalty Pharma plc as a party to the existing Purchase Agreement.","At closing, each seller will subscribe for Class B ordinary shares equal to the Class E shares of RPH received.","Subscription price is nominal $0.000001 per share, paid in cash by sellers to the company.","Amendment facilitates the transaction to acquire all equity interests of RP LLC, disclosed in January 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159830,"accession_number":"0001193125-25-077950","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Royalty Pharma appoints Vlad Coric, M.D., to Board of Directors effective April 7, 2025.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Vlad Coric appointed to Royalty Pharma Board effective April 7, 2025.","He is Chairman and CEO of Biohaven, led Nurtec ODT approval and $13B sale to Pfizer.","Coric will stand for election at 2025 Annual Meeting; if elected, expected to join Compensation Committee.","Board determined Coric meets Nasdaq independence standards; will receive standard independent director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178192,"accession_number":"0001193125-25-023988","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q4 2024: Royalty Receipts +12% to $729M; 2025 guidance $2.9B–$3.05B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Portfolio Receipts $742M in Q4 (+1% YoY); FY 2024 $2,801M (-8% due to $525M Biohaven milestones in 2023).","Net cash from operations $743M in Q4, $2,769M for FY. Adjusted EBITDA $669M (Q4), $2,565M (FY).","2025 Portfolio Receipts guidance $2,900M–$3,050M (+4–9% growth), excluding future transactions.","Capital deployed $2.8B in 2024; new $3B share repurchase program authorized in Jan 2025, $2B planned in 2025.","Acquisition of external manager RP Management for ~$1.1B in equity/cash/debt; expected Q2 2025 close."],"consensus_eps_estimate":null,"consensus_eps_actual":1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":2263576000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178191,"accession_number":"0001193125-25-005038","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Royalty Pharma presents at J.P. Morgan; no financial details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation at 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.","Filing references a pending corporate simplification transaction (see Jan 10, 2025 8-K).","No financial results, guidance, or portfolio updates provided in this exhibit.","Shareholder vote required for transaction; proxy statement to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178190,"accession_number":"0001193125-25-004097","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma expects FY 2024 Portfolio Receipts ~$2.8B, at upper end of guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 Portfolio Receipts expected ~$2,800M (upper end of $2,750-$2,800M range).","Underlying Royalty Receipts growth ~13% YoY; Adjusted EBITDA ~$2,560-2,570M.","Capital deployed $2.8B in 2024, record $925M synthetic royalty deals (Rytelo, Niktimvo, Yorvipath).","Late-stage pipeline potential peak royalties >$1.2B/yr; key catalysts: pelacarsen (Phase 3 2025), aficamten (PDUFA Sept 2025).","Announced acquisition of external manager and increased share repurchase commitment (details not provided in this release)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":2263576000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178189,"accession_number":"0000950103-25-000393","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Royalty Pharma to acquire external manager for ~$1.1B, announces $3B buyback","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires manager RP Management for ~$1.1B: $200M cash, $380M debt assumed, 24.5M RPH shares (4% of shares).","Cumulative cash savings >$1.6B over ten years; >$100M in 2026 rising to >$175M in 2030.","Board approves $3B share repurchase; intends $2B in 2025 subject to market conditions.","Equity consideration vests over 5-9 years; Pablo Legorreta's shares vest in 5 years, others in 9.","Transaction requires shareholder approval; expected close Q2 2025; ~25% of shares committed to vote in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194860,"accession_number":"0001193125-24-287172","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Royalty Pharma amends exchange agreement for internal EPA holdings restructuring","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Amended Exchange Agreement transfers Holdings C Share from RPI EPA Holdings to RPI EPA Vehicle.","Articles of association of Royalty Pharma Holdings Limited amended and restated.","Restructuring involves equity performance awards (EPA) entity substitution.","No changes to publicly traded Royalty Pharma plc's operations or financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194859,"accession_number":"0001193125-24-251698","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q3 portfolio receipts up 15% to $735M; raises FY guidance to $2.75-2.8B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Royalty Receipts grew 15% to $732M; Portfolio Receipts $735M, driven by Trelegy, Evrysdi, cystic fibrosis franchise.","Full-year 2024 Portfolio Receipts guidance raised to $2.75B-$2.8B (from $2.7B-$2.775B); Royalty Receipts growth 11-13%.","Capital Deployment of ~$1.2B in Q3; acquired synthetic royalties on Niktimvo ($350M) and Yorvipath ($150M).","Net cash from operations $704M; repurchased ~3M shares for $95M during Q3; cash and equivalents $950M.","FDA approvals for Cobenfy (schizophrenia), Tremfya (ulcerative colitis), Voranigo (glioma) benefit royalty portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":1669935000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211151,"accession_number":"0001193125-24-227407","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"FDA approves KarXT (Cobenfy) for schizophrenia; triggers $25M milestone for Royalty Pharma from PureTech deal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved KarXT (xanomeline-trospium) for adult schizophrenia; BMS to market as Cobenfy.","Royalty Pharma's March 2023 PureTech deal: $100M upfront, up to $400M milestones, 3% royalty on sales up to $2B (then 1%).","Approval triggers $25M milestone payment from Royalty Pharma to PureTech.","Approval validates Royalty Pharma's investment and unlocks potential future royalty revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211150,"accession_number":"0001193125-24-196475","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q2 Portfolio Receipts $608M (+12% YoY); raises FY 2024 guidance to $2.7-2.775B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Royalty Receipts grew 11% to $605M, driven by cystic fibrosis franchise, Trelegy (+32%), Tremfya (+34%), and Evrysdi (+91%).","Raised FY 2024 Portfolio Receipts guidance: $2,700M-$2,775M (previous $2,600M-$2,700M), implying 9-12% Royalty Receipts growth.","Capital deployed ~$2B YTD including $905M for Voranigo (approved Aug 6) and $575M expanded Cytokinetics collaboration.","Issued $1.5B senior notes at 5.5% in June; total debt $7.8B at 3.1% avg cost; repurchased 4M shares for $115M YTD.","Trodelvy Phase 3 TROPiCS-04 failed survival endpoint; BioCryst discontinued BCX10013 – potential portfolio headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":1105245000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211149,"accession_number":"0001193125-24-195397","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"FDA approves Voranigo; Royalty Pharma pays $905M milestone, expects >$150M/yr royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved Voranigo (vorasidenib) for IDH1/2 mutant diffuse glioma on August 6, 2024.","Royalty Pharma pays $905M to Agios upon approval under May 2024 royalty agreement.","Royalty Pharma receives 15% royalty on U.S. net sales up to $1B, 12% above $1B.","Peak annual sales projected >$1B; annual royalties >$150M through 2038."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229689,"accession_number":"0001193125-24-164004","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Royalty Pharma increases Evrysdi royalty stake to 90.5% for $242M from PTC option exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PTC exercised option to sell half its retained Evrysdi royalty to Royalty Pharma for ~$242M upfront.","Royalty Pharma's Evrysdi royalty ownership increases from 81% to 90.5% (before cap).","Evrysdi (SMA drug) generated 2023 sales of ~CHF 1.4B ($1.6B), up 39% YoY at CER.","Total upfront investment in Evrysdi royalties now $1.9B; effective royalty rate 7.2%-14.5%.","PTC retains option to sell remaining 9.5% royalty for $250M less royalties received until Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229688,"accession_number":"0001193125-24-158417","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Royalty Pharma closes $1.5B senior notes offering across three tranches","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M 5.150% notes due 2029, $500M 5.400% notes due 2034, $500M 5.900% notes due 2054.","Interest payable semiannually on March 2 and September 2, starting March 2025.","Notes are senior unsecured guaranteed by Royalty Pharma Holdings Ltd.","Issuer may redeem notes at specified prices; change-of-control repurchase provisions apply.","Offering closed June 10, 2024; aggregate principal $1.5B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229687,"accession_number":"0001193125-24-156183","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Royalty Pharma shareholders elect all eight directors at June 6 AGM; all proposals pass","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with 457M–482M For votes; broker non-votes 24.8M per nominee.","Advisory say-on-pay approved (448.1M For, 37.7M Against); auditor Ernst & Young LLP ratified (510.5M For).","UK statutory accounts, directors' remuneration policy and report all passed with majority support.","Share allotment authorities (proposals 9 & 10) approved with over 455M For votes each.","Quorum of 85.49% of combined voting power represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229686,"accession_number":"0001193125-24-154347","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Royalty Pharma prices $1.5B senior notes offering across three tranches","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M 5.150% Senior Notes due 2029, $500M 5.400% due 2034, and $500M 5.900% due 2054.","Notes are senior unsecured and guaranteed by Royalty Pharma Holdings Ltd.","Offering expected to close on June 10, 2024, subject to customary conditions.","Underwriting agreement with BofA, Citigroup, J.P. Morgan, Morgan Stanley, and TD Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229685,"accession_number":"0001193125-24-149338","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"J&J Phase 3 seltorexant meets all endpoints; Royalty Pharma holds mid-single-digit royalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["J&J's Phase 3 MDD3001 trial of seltorexant met all primary and secondary endpoints in MDD with insomnia.","Seltorexant is a first-in-class orexin-2 receptor antagonist; no approved therapies exist for MDD with insomnia.","Royalty Pharma is entitled to a mid-single-digit royalty on worldwide net sales of seltorexant.","J&J previously estimated non-risk adjusted peak sales potential of $1B–$5B for seltorexant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229684,"accession_number":"0001193125-24-134758","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q1 Royalty Receipts +14% to $705M; FY2024 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Portfolio Receipts of $717M, down 37% from $1,131M YoY due to $475M Biohaven milestone in Q1 2023.","Royalty Receipts grew 14% to $705M, led by Evrysdi, Trelegy, and the cystic fibrosis franchise.","Full-year 2024 Portfolio Receipts guidance reaffirmed at $2.6B–$2.7B, with Royalty Receipts growth of 5%–9%.","Announced ~$525M acquisition of royalties on Sanofi’s frexalimab (Phase 3 multiple sclerosis); $5.9B total liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":567978000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248199,"accession_number":"0001802768-24-000010","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q4 Portfolio Receipts $736M (-31% YoY); FY23 $3,049M (+9%); FY24 guide $2.6-2.7B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Portfolio Receipts Q4 $736M (down 31% YoY due to prior-year accelerated Biohaven payments); FY23 $3,049M (+9%).","FY24 guidance: Portfolio Receipts $2.6B-$2.7B, implying royalty receipts growth of 5-9% YoY.","Announced new transactions up to $4.0B in 2023; capital deployed $2.2B in 2023.","Repurchased ~10M shares for $305M in 2023 under $1B buyback program.","Positive clinical updates: aficamten Ph3 success, BMS to acquire Karuna, Novartis to acquire MorphoSys."],"consensus_eps_estimate":null,"consensus_eps_actual":2.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":2354554000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248198,"accession_number":"0001193125-24-024761","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Royalty Pharma details royalties and funding from Novartis acquisition of MorphoSys at €68/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Pharma holds 3% royalty on pelabresib (myelofibrosis) and tulmimetostat (EZH2 inhibitor) future sales; NDA submission expected mid-2024.","Tiered mid-single digit royalty on Tremfya (J&J; $3.1B sales FY2023) and 3.3%-4.2% effective royalty on Roche's trontinemab for Alzheimer's.","MorphoSys to make 36 payments totaling ~$660M (2.2x funded $300M) to repay Development Funding Bonds, starting Q4 2024.","Royalty Pharma's 1,337,552 MorphoSys shares valued at ~$100M at proposed Novartis acquisition price.","Royalty Pharma had committed up to $2.025B funding to MorphoSys in July 2021 strategic partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248197,"accession_number":"0001193125-24-003879","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma expects 2023 Portfolio Receipts of ~$3.05B, exceeding upper guidance; 11% underlying growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Portfolio Receipts for FY2023 expected ~$3.05B, above prior guidance of $2.95B-$3.0B; underlying growth 11% YoY.","Net cash from operations for FY2023 ~$2.98B-$2.99B.","Announced transactions since 2020 total ~$13B, including $4.0B in 2023; synthetic royalty transactions at record $775M.","Capital deployment target of $10B-$12B from 2022-2026; longer-term potential to double annual deployment to $4B-$5B.","Portfolio investments since 2020 expected to add ~$1.2B to Portfolio Receipts in 2025 based on consensus sales forecasts."],"consensus_eps_estimate":null,"consensus_eps_actual":2.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":2354554000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265674,"accession_number":"0001193125-23-304012","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Royalty Pharma ups revolving credit facility to $1.8B, extends majority to Dec 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowing capacity increased from $1.5B to $1.8B via Amendment No. 3.","$1.69B of commitments extended to December 22, 2028; $110M remains at Oct 31, 2027.","Facility remains unsecured; interest based on SOFR/base rate plus applicable margin.","Covenants include max leverage ratio of 4.00x (4.50x post material acquisition) and min coverage of 2.50x.","Proceeds for general corporate purposes; amendment effective December 22, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265673,"accession_number":"0001193125-23-303786","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cytokinetics' aficamten Phase 3 success triggers $75M milestone for Royalty Pharma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cytokinetics announced positive Phase 3 SEQUOIA-HCM results for aficamten in symptomatic obstructive HCM.","Royalty Pharma holds a 4.5% global royalty on aficamten (3.5% on sales >$1B) as per Jan 2022 agreement.","Royalty Pharma provided $50M commercial launch capital; Cytokinetics can now draw $75M milestone.","Additional $100M milestone payable upon FDA acceptance of aficamten NDA.","Full results to be presented at upcoming medical conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265672,"accession_number":"0001193125-23-278946","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Royalty Pharma files prospectus for 383,000 shares under equity incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Prospectus supplement covers up to 383,000 Class A ordinary shares.","Shares to be awarded to employees and consultants of RP Management LLC.","Awards granted under the RP Management Equity Incentive Plan.","Legal opinion from Davis Polk & Wardwell filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265671,"accession_number":"0001802768-23-000027","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q3 2023: $637M Adj Cash Receipts (+7% YoY); raises FY23 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted Cash Receipts of $637M (+7% YoY); operating cash flow $574M (+6%).","Raised FY 2023 guidance for Adjusted Cash Receipts to $2,950M-$3,000M (prev. $2,900M-$2,975M).","Year-to-date announced transactions of up to $3.8B, including $2.1B in upfront payments.","CF franchise royalties $238M (+14%); Trelegy $58M (+36%); Evrysdi $16M (+64%)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1758486000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265670,"accession_number":"0001193125-23-258997","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Royalty Pharma draws $350M from revolver to fund Evrysdi royalty purchase","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Subsidiary borrowed $350M under $1.5B five-year unsecured revolver on Oct 18, 2023.","Proceeds to partially fund previously announced purchase of additional Evrysdi royalties from PTC Therapeutics.","Revolving credit facility originally dated Sept 15, 2021; amended Oct 31, 2022 (exhibit 10.1).","Borrowing is within existing $1.5B capacity; no other material terms changed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282881,"accession_number":"0001802768-23-000022","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q2 adj cash receipts $545M (+4%); raises 2023 guidance to $2.9-2.975B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net cash from ops $608M (+6% YoY); Adjusted Cash Receipts $545M (+4%), Adjusted EBITDA $498M (+4%).","Raised 2023 Adj Cash Receipts guidance to $2.900B-$2.975B from $2.85B-$2.95B, excluding new transactions.","YTD announced transactions up to $1.7B, including $659M upfront; began share repurchases.","CF franchise royalties +13% to $206M; Trelegy added $37M, Spinraza $13M; Imbruvica -22%, Xtandi -22%.","Adjusted Cash Flow $512M (+6%) driven by EBITDA growth and higher net interest received."],"consensus_eps_estimate":null,"consensus_eps_actual":1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":1222173000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302227,"accession_number":"0001193125-23-173169","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Royalty Pharma shareholders elect all 10 director nominees; all AGM proposals pass","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All ten director nominees elected, with support ranging from 79.2% (Gregory Norden) to 99.7% (M. Germano Giuliani).","Non-binding say-on-pay approved: 483.9M for (94.5% of votes cast excluding 22M broker non-votes).","Ratification of Ernst & Young as independent auditor passed with 534.2M for (99.98%).","UK statutory accounts and auditor reappointment also approved with >99% support; no broker non-votes on those proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302226,"accession_number":"0001802768-23-000013","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q1 adjusted cash receipts $1,131M (+87% YoY); reaffirms FY guidance $2,850-2,950M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted Cash Receipts $1,131M, +87% YoY; underlying growth 11% ex-Zavzpret milestone and Biohaven payments.","GAAP net cash from ops $1,034M (+125% YoY) includes $475M Zavzpret milestone and $35M Airsupra payment.","Announced up to $1.6B in new royalty deals (Spinraza, pelacarsen, KarXT) and $1.0B share buyback program.","Reaffirmed FY23 Adjusted Cash Receipts guidance $2,850-2,950M (underlying growth 4-9% ex-milestones).","Portfolio milestones: FDA approvals for Zavzpret, Airsupra, Trodelvy; positive Xtandi Phase 3 data."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":683971000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321892,"accession_number":"0001193125-23-081464","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Royalty Pharma adopts Articles amendments to enable share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Pharma Holdings Ltd amended its Articles of Association on March 24, 2023.","Amendments facilitate the share repurchase program announced by Royalty Pharma plc on March 27, 2023.","No other changes to governance or fiscal year were made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321891,"accession_number":"0001193125-23-070732","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Royalty Pharma receives $475M milestone from Pfizer on Zavzpret approval, raises 2023 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $475M accelerated milestone payment from Pfizer following FDA approval of Zavzpret (zavegepant) for acute migraine.","Raised full-year 2023 Adjusted Cash Receipts guidance to $2,850M-$2,950M from prior $2,375M-$2,475M.","Royalty Pharma will now earn royalties on net sales of both Nurtec ODT and Zavzpret.","CEO Pablo Legorreta noted the milestone provides additional capital for redeployment to create long-term shareholder value.","Guidance excludes contributions from future transactions and assumes no major unforeseen adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321890,"accession_number":"0001802768-23-000005","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q4 Adj Cash Receipts up 96% YoY; guides FY23 $2.375-$2.475B excl. $475M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 Adj Cash Receipts $1,064M (+96% YoY); FY 2022 $2,789M (+31%).","Q4 GAAP operating cash flow $570M (+16% YoY); FY $2,144M (+6%).","Announced transactions up to $3.5B in 2022, including $2.0B in upfront payments.","FY 2023 guidance: Adj Cash Receipts $2,375M-$2,475M, underlying growth 4-9% prior to Biohaven payments; excludes potential $475M zavegepant milestone.","In 2023, agreed to provide $500M upfront to Ionis Pharmaceuticals for a new partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":2237215000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321889,"accession_number":"0001193125-23-004274","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma expects 2022 Adj. Cash Receipts ~$2.79B, at upper end of guidance; 31% YoY growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2022 Adjusted Cash Receipts (non-GAAP) expected ~$2,785-2,790M, towards upper end of $2,750-2,800M guidance; 31% YoY growth.","2022 GAAP operating cash flow expected ~$2,140-2,150M.","Since 2020, announced $10B in transactions; investments expected to add ~$1B to annual Adjusted Cash Receipts in 2025.","Added royalties on six new therapies in 2022, including Trelegy (respiratory), olpasiran, aficamten, and MK-8189.","Capital deployment target $10-12B over five years; potential to double to $4-5B annually longer term."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":2237215000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339975,"accession_number":"0001193125-22-296619","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["2.06"],"status":"ready","headline":"Royalty Pharma records $273.6M impairment on gantenerumab royalty after Roche halts trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-cash impairment charge of $273.6M related to gantenerumab financial royalty asset.","Roche discontinued gantenerumab trials Nov 30, 2022 after GRADUATE I/II missed primary endpoint.","Impairment reflects entire net carrying value as of Sept 30, 2022; no impact on non-GAAP results.","No portion of the charge relates to future cash expenditures.","Charge will be recorded in Q4 2022 under GAAP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339974,"accession_number":"0001802768-22-000043","cik":1802768,"company_name":"Royalty Pharma plc","ticker":"RPRX","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Royalty Pharma Q3 2022: Adjusted Cash Receipts up 2% to $597M; raises FY 2022 guidance to $2,750-2,800M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net cash from operating activities $539M (+15% YoY); Adjusted Cash Flow $441M (+26% YoY).","Raised FY 2022 Adjusted Cash Receipts guidance to $2,750-2,800M, including $458M from Pfizer's Biohaven acquisition acceleration.","Announced up to $3.0B YTD capital deployment, including R&D funding collaboration with Merck (MK-8189).","Royalty receipts: Cystic fibrosis franchise $208M (+14%), Trelegy added $43M, Januvia/Janumet down 97% to $1M.","Adjusted EBITDA $548M (+3%); operating costs 8% of Adjusted Cash Receipts."],"consensus_eps_estimate":null,"consensus_eps_actual":1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":1671467000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31379822272.398193,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-08T23:59:59+00:00|339974"}